| Description |
Rezafungin (Biafungin) is a next-generation, broad-spectrum, and long-lasting echinocandin. Rezafungin shows potent antifungal activity against Candida spp., Aspergillus spp., and Pneumocystis spp.[1][2].
|
| Related Catalog |
|
| In Vivo |
Rezafungin (Biafungin) shows potent in vivo efficacy as prophylaxis against Pneumocystis in an in vivo mouse infection model[1]. Animal Model: C3H/HeN mice[1] Dosage: 1 mg/kg Administration: Intraperitoneal injection; once daily for 6 days Result: Significantly reduced nuclei and asci burdens.
|
| References |
[1]. Melanie Cushion, et al. Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia. VOLUME 25, ISSUE 3, SUPPLEMENT, S366, MARCH 01, 2019. [2]. Sofjan AK, et al. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 Sep;14:58-64.
|
